• These conventional imaging methods are unable to specifically identify treatment-induced changes in a timely manner, limiting the ability to distinguish pseudoprogression from true tumor progression.
• Emerging imaging techniques that rely on specific underlying biological tumor properties lack validation and standardization, rendering them non-useful for current clinical assessment of GBM.
• Appropriate endpoints and methodologies for these emerging imaging methods need to be determined before they can be reliably included in clinical trials for GBM.
• Advanced imaging studies, focusing on the non-enhancing invasive margin, are needed for assessing regional tumor response to treatment for further understanding of GBM invasion and recurrence, and improvement of patient management.
SUMMARY
Glioblastoma demonstrates imaging features of intratumor heterogeneity that result from underlying heterogeneous biological properties. This stems from variations in cellular behavior that result from genetic mutations that either drive, or are driven by, heterogeneous microenvironment conditions. Amongst all imaging methods available, only T 1 -weighted contrast-enhancing and T 2 -weighted fluid attenuated inversion recovery are used in standard clinical GBM assessment and monitoring. Advanced imaging modalities are still considered emerging techniques as appropriate endpoints and robust methodologies are missing from clinical trials. Discovering how these images specifically relate to the underlying tumor biology may aid in improving quality of clinical trials and understanding the factors involved in regional responses to treatment, including variable drug uptake and effect of radiotherapy.
Upon validation and standardization of emerging MR techniques, providing information based on the underlying tumor biology, these images may allow for clinical decision-making that is tailored to an individual's response to treatment.
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Even under optimal treatment conditions, median survival is only 14 months with a 26% 2-year survival rate [1] and patient death results from inevitable tumor progression.
Recurrence is often local and not easily detected using conventional magnetic resonance imaging (MRI). Amongst all options available for treatment, extent of resection is the only variable that neurosurgeons can affect [2] . In spite of the incorporation of 5-Aminolevulinic acid (5-ALA) improving maximal resection and 6-month progression free survival (PFS) [3] , poor drug delivery and relative radiotherapy (RT) resistance [4] contribute to poor prognosis.
Though the progress in GBM management has been disappointing, with the single major advancement in the past decades being the incorporation of RT with concomitant and adjuvant temozolomide (TMZ) [1] , there has been exponential growth in the advancements of MRI techniques for non-invasive characterization of GBM. In parallel, advancements in genomic tool development for molecular analysis on a genome-wide level have also been ongoing [5] . With this, work has begun for merging imaging information with that of the underlying biology driving intratumor heterogeneity of GBM.
Intratumor heterogeneity of glioblastoma: what is it and why does it occur?
Tumor heterogeneity refers to biological differences between malignant cells in a same cancer, where variations in genetic alterations and phenotypic inconsistencies (including cellular metabolism, resilience and behavior) can drive tumor cell diversity within an individual tumor (intratumor heterogeneity) or among patients with the same tumor (intertumor heterogeneity) [6] .
During tumor development, malignant cells evolve together with the extra-cellular matrix, microvasculature, stromal and immune cells [7] . Regional variations that arise from this coevolution are presumed to be a partnership of distinct ecosystems of cells, for which the microenvironment would be, in the primary instance, influenced by inconsistencies in vasculature and blood supply. The resulting microenvironment conditions would include subsequent regional inflammation, hypoxia and acidosis with limited glucose supply. This would set the scene for selective pressures, giving rise to regional cellular adaptations -a Darwinian concept of adaptive response. Heterogeneity, therefore, can arise through extrinsic mechanisms that confer functional differences to the malignant cells [8] . In a recent study, GBM cells isolated from two different microenvironments, the tumor core and margin, each demonstrated different phenotype and stem-cell signature whilst propagated within the same culture conditions [9] . Tumor cell diversity can also arise through genomic instability and differential response of clones to therapy, where cellular proliferation does not result in clusters of identical cells. Instead, many sub-clones are developed through complex spatial and temporal evolutionary trajectories [6, 10, 11] .
What is the implication of intratumor heterogeneity on management of glioblastoma?
Intratumor heterogeneity is a dynamic state, which is most likely the primary force driving differential responses to therapy, development of treatment resistance and, ultimately, tumor recurrence [8, [10] [11] [12] . RT and TMZ create a selective evolutionary pressure on GBM cells to which they are exposed. Microenvironment conditions that prevent treatment from having effect may result in surviving cells that proliferate to form clusters of cancer cells with conferred resistance, meaning that a single drug may not be enough for efficient treatment.
Combined therapies appear to be the way forward; these would need to target trunk alterations of clonally dominant tumor drivers [13] . Problematically, passenger mutations can become drivers in response to environmental pressures caused by treatment [14] .
Therapy of GBM requires, in addition to target tumor cells being in cycle, tissue oxygenation. This, in turn, requires adequate blood supply. Though angiogenesis is a feature of GBM, the new circulation systems are usually tortuous, leaky and chaotic, creating an environment of inconsistent blood supply with resultant regional hypoxia and interstitial hypertension [15, 16] , in spite of increased angiogenesis. Hypoxia reduces the effects of radiation-induced DNA damage of GBM cells (the oxygen-fixation hypothesis) [17] and recurrence often occurs within a few centimeters of the primary lesion [18] . Additionally, the go or grow hypothesis [19] , states that the migrating phenotype is different to that of the proliferative one, where invading cells are not proliferative and, therefore, not affected by RT. The heterogeneously leaky microvasculature also results in increased interstitial fluid pressures (IFP) and nonuniform drug delivery [16, 20] , with intrinsic cellular properties also playing a role [21] .
Furthermore, secondary somatic mutations emerge as result of therapies, contributing to changes in the tumor clonal architecture [13] and activation of genes of drug resistance.
Conventional imaging for monitoring intratumor heterogeneity of glioblastoma: why is it not enough?
Currently, conventional imaging ( Table 1) 
Diffusion imaging
Diffusion imaging essentially provides information pertaining to the nature of water molecule movement within biological tissue. As the biology of the edematous invasive margin is different to that of the tumor bulk [9] , the development of imaging techniques for GBM characterization, that also focus on the margin as a region of interest, is paramount for the incorporation of advanced imaging in assessment criteria of GBM.
DTI is a modification of DWI that is sensitive to the anisotropic diffusion of water along axonal fibers, where one can decompose the diffusion tensor into isotropic (p-) and anisotropic (q-) components. By assessing the disruption of white matter (identified as a decrease in q) with adjacent edema (identified as an increase in p), DTI has allowed for differentiation of the tumor bulk from the invasive margin [26, 27] , which can extend beyond the T 2 -weighted FLAIR abnormality (Figure 2) . The underlying biology observed with DTI beyond that of white matter integrity is not well described, making it a technique that is limited in providing detailed information of the microenvironment. DTI has, however, been used to identify patterns of recurrence [28] and white matter invasion in GBM [29] , with improved delineation of the invasive margin [30] . cytotoxic edema, during which cells swell due to ion imbalances caused by cell wall damage, or 2) recurrent tumor. Increased ADC after cytotoxic therapy, also an early sign of possible pseudoprogression [33] , can indicate either 1) cell death or necrosis, where one finds increased water motility in extracellular spaces, or 2) an inflammatory response with subsequent peritumoral edema. With inflammation, however, comes an inflammatory cell response, which may contribute to possible decreases in regional ADC, further warranting caution when using ADC to assess and monitor GBM. In an anti-angiogenic therapy-setting, histogram studies vary. One has found low ADC to correlate with better survival patterns [34] . A subsequent analysis associated high ADC with increased levels of extracellular matrix protein gene expression [35] , believed to enhance tumor invasion by promoting collagen-enriched matrices for rapid migration [36] . Other studies have, conversely, found an association of low ADC with poor outcome [37] in recurrent GBM. The latter comes from a multicenter study and is in agreement with more specific histological analyses of regional ADC demonstrating an inverse correlation between tumor cell density and ADC [38] . Low ADC has also been suggested for use during image-guided biopsies of tumor-containing regions in areas of FLAIR abnormality [39] .
Changes in regional ADC are apparent before changes in conventional imaging features [40] . Functional diffusion maps (fDM), which take the intratumoral heterogeneity of ADC into account, produce regional color maps according to whether ADC-values have increased, decreased or remained unchanged. Studies have used fDMs to predict responses to therapy as early as three weeks from start of chemo-RT [41, 42] . Perfusion imaging PWI dynamic susceptibility contrast imaging (DSCI) measures of relative cerebral blood volume (rCBV) correlate with regional tumor vascularity [45, 46] and cellular proliferation [47] .
As with diffusion, perfusion can vary significantly with changes in cell density, edema and necrosis, and various biological situations can be presumed during regional assessment [48] . Within the 'necrotic core' of contrast-enhanced images (Figure 4) , regional low rCBV would presumably represent a cell population that was unable to adapt to a hypoxic and/or acidic environment. A poorly perfused, yet cellular, region may be indicative of an adaptive cell niche (Figure 4) . This niche is of importance as it implies the evolution of a cell population resistant to regular causes of necrosis or apoptosis-these may be resistant to current chemo-RT. Dynamic contrast enhancement (DCE) MRI relies on compartmentbased tracer kinetic models, where certain parameters can be used to describe BBB integrity and leakiness of blood vessels [49, 50] . These parameters can be used to indirectly describe biological properties, including relative IFP. However, most work, with the exception of one [50] , has focused primarily on summary statistics, such as the median or mean, of DCE parameters without taking into account the regional heterogeneity of GBM. As with ADC, extreme values within PWI niches result in mean values that do not necessarily represent what is happening within the entire lesion. As mentioned, resistance to drug delivery is caused, at least in part, by impaired microvasculature and lymphatic system function, leading to increased IFP [16] , making DCE another potential PWI method for characterizing GBM based on regional IFPs, which may be responsible for regional inadequate drug uptake in both the tumor bulk and the non-enhancing invasive margin.
Following chemo-RT, increased perfusion measures can occur prior to changes in T 1 contrast-enhancement [51] . PWI measures have been utilized for differentiating pseudoprogression from true recurrence [52, 53] and studies have found certain parameters, including rCBV [47, 51] , to change in the non-enhancing margin of GBM [54] . This makes standardized PWI [49, 55] a potential tool for future analyses of, not only the enhancing tumor bulk, but also the non-enhancing component that is left behind post-surgery.
Spectroscopic imaging
Multivoxel MRS, or chemical shift imaging (CSI), reveals changes in tissue metabolism.
Metabolic data have been used not only independently, but also as complementary techniques to improve tumor characterization in combination with parameters of DWI [56, 57] and PWI [58, 59] . CSI also provides additional information for better understanding of the microenvironment, such as increased cellular density, identified as an increase in levels of Choline (Cho) [56] ; neuronal damage, identified as a decrease in N-acetylaspartate (NAA) levels; and tumor metabolism with associated hypoxia and acidosis, identified as increased lactate and lipid production [60] . Studies looking at margin delineation [61] and characterization using CSI have reported increased Cho/NAA ratio in the non-enhancing component of GBM [62] [63] [64] , where an increase of this ratio coincides with an increase in degree of invasion [65] . Conversely, studies have correlated Cho/NAA ratio with tumor cell proliferation [61, 66] . This conflict in findings, where the similar results are reported to correlate with proliferation and invasion, two cellular processes reported to carry different phenotypic characteristics in GBM, highlights the need for caution when relying on MRS CSI for regional characterization of these tumors. Nonetheless, this imaging approach demonstrates potential, especially when combining this modality with other advanced imaging methods.
Positron emission tomography
Using a tracer to functionally image tumor metabolic activity, PET has been used in studies of GBM treatment effects. in assessing effects of RT [67] , including identification of true progression [68] , it appears to be less effective than DWI under direct comparison [69] .
F-fluorothymidine (FLT), in addition to MET, is a useful biomarker of cellular proliferation in GBM, with the regional heterogeneity of uptake correlating to with MIB-1 labelling index [70] . This, in turn, correlates with FLT transport across the BBB [71] . Though contrast with FLT is better than with FDG [72] , uptake is BBB-determined, which poses a problem in GBM analysis, whose BBB is characteristically leaky around contrast-enhancing components. Effects of RT have been examined using FLT. These findings, however, have largely involved animal studies [73] . To assess potential malignancy based on cellular membrane metabolism, 18F-fluorocholine (CHO PET) has gathered attention in GBM monitoring, with increased CHO uptake being characteristic of high-grade gliomas [74] . To assess response to antiangiogenic therapies, 18 F-fluciclatide, has been used to visualize regional integrin, which plays a key role in angiogenesis [75] . Furthermore, hypoxia markers, such as 18 Ffluoromisonidazole (FMISO), continue to be investigated for predicting response to RT [76] and bevacizumab. As drug delivery in tumors is heterogeneous [20] , PET tracers for specific drugs with positron emitters would produce images of tracer uptake that are representative of regional drug uptake, making PET an imaging tool of significant potential.
Conclusion & Future Perspective
The complex dynamics of biological systems in GBM result in heterogeneous and inconsistent imaging features. It is becoming evident, however, that regional variations within GBM result in specific imaging characteristics. Very little is known of the molecular and genomic properties found within separate niches in GBM, but having an idea of the microenvironment they inhabit, could provide details of the adaptive strategies undertaken for cell survival. Therefore, a valuable metric for future GBM analysis could involve assessment of MRI-defined 'habitat' changes in response to therapy. This would be beneficial in personalized treatment, such as the implementation of boost RT dosing in regions of high risk.
Though the potential appears promising, the use advanced imaging as surrogate measures of tumor biology carry limitations. In addition to inter-observer variability, limitations include enhancing variability, measurement variability, as well as false positives and negatives [77] .
This highlights the need for future refinement in the assessment criteria with a particular focus on standardization [49, 55] of imaging characteristics along with clearer understanding of underlying biological properties, whether they are at the cellular, molecular or genetic level. This would potentially minimize errors caused by intrinsic parametric variation, and enhance the accuracy of assessing response to treatment [22] in a multicenter setting.
Determining the added value of assessing non-enhancing tumor progression, as a measure of clinically relevant and treatment-related change, and incorporating into the assessment criteria, may too be a way forward. This will most likely be achieved with identification of appropriate endpoints in multicenter trials. Additionally, a shift to three-dimensional assessment [25] will improve the understanding of regional spatial dynamics. Furthermore, assessing regional volumes, as opposed to areas, would preserve statistical power of results whilst using a smaller patient cohort.
As future directions for GBM management probably involve multimodal therapy directed at multiple sub-regions, the advantages obtained with a detailed understanding of regional imaging properties, and the underlying eco-biology, will contribute to improved strategies for personalized medicine of GBM.
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